MA27045A1 - Indoles, benzofurannes et benzothiophenes a substituant triamide, utiles comme inhibiteurs de secretion de la proteine de transfert des triglycerides microsomaux et/ou de l'apolipoproteine b (apo b) - Google Patents

Indoles, benzofurannes et benzothiophenes a substituant triamide, utiles comme inhibiteurs de secretion de la proteine de transfert des triglycerides microsomaux et/ou de l'apolipoproteine b (apo b)

Info

Publication number: MA27045A1
Authority: MA; Morocco
Prior art keywords: benzothiophenes; benzofurans; triamide; apolipoprotein; apo
Prior art date: 2001-06-28

Application number

MA27457A

Other languages

English (en)

Inventor

Peter Bertinato

Alan Elwood Blize

Brian Scott Bronk

Hengmiao Cheng

Hiep Huatan

Jin Li

Clive Philip Mason

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-28

Filing date

2003-12-22

Publication date

2004-12-20

2003-12-22 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-12-20 Publication of MA27045A1 publication Critical patent/MA27045A1/fr

Links

MPNFMCAOBNNFJF-UHFFFAOYSA-N 2,3-diphenyl-1-benzofuran Chemical class C1=CC=CC=C1C1=C(C=2C=CC=CC=2)C2=CC=CC=C2O1 MPNFMCAOBNNFJF-UHFFFAOYSA-N 0.000 title 1
101710095342 Apolipoprotein B Proteins 0.000 title 1
102100040202 Apolipoprotein B-100 Human genes 0.000 title 1
102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 title 1
150000002475 indoles Chemical class 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
108010038232 microsomal triglyceride transfer protein Proteins 0.000 title 1
230000028327 secretion Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Furan Compounds (AREA)
Hydrogenated Pyridines (AREA)

MA27457A 2001-06-28 2003-12-22 Indoles, benzofurannes et benzothiophenes a substituant triamide, utiles comme inhibiteurs de secretion de la proteine de transfert des triglycerides microsomaux et/ou de l'apolipoproteine b (apo b) MA27045A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US30164401P	2001-06-28	2001-06-28

Publications (1)

Publication Number	Publication Date
MA27045A1 true MA27045A1 (fr)	2004-12-20

Family

ID=23164253

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA27457A MA27045A1 (fr)	2001-06-28	2003-12-22	Indoles, benzofurannes et benzothiophenes a substituant triamide, utiles comme inhibiteurs de secretion de la proteine de transfert des triglycerides microsomaux et/ou de l'apolipoproteine b (apo b)

Country Status (46)

Country	Link
US (5)	US6720351B2 (fr)
EP (1)	EP1404653B1 (fr)
JP (1)	JP4139325B2 (fr)
KR (2)	KR100575919B1 (fr)
CN (2)	CN1880304B (fr)
AP (1)	AP1649A (fr)
AR (1)	AR036158A1 (fr)
AT (1)	ATE405548T1 (fr)
AU (1)	AU2002307839B2 (fr)
BG (1)	BG108487A (fr)
BR (1)	BR0210616A (fr)
CA (1)	CA2451474C (fr)
CR (1)	CR7151A (fr)
CY (1)	CY1108407T1 (fr)
CZ (1)	CZ20033558A3 (fr)
DE (1)	DE60228447D1 (fr)
DK (1)	DK1404653T3 (fr)
EA (1)	EA007008B1 (fr)
EC (1)	ECSP034925A (fr)
EE (1)	EE05452B1 (fr)
ES (1)	ES2307799T3 (fr)
GE (2)	GEP20053720B (fr)
GT (1)	GT200200136A (fr)
HR (1)	HRP20031051B1 (fr)
HU (1)	HU229551B1 (fr)
IL (1)	IL158516A0 (fr)
IS (1)	IS2603B (fr)
MA (1)	MA27045A1 (fr)
MX (1)	MXPA03011707A (fr)
MY (1)	MY129328A (fr)
NO (1)	NO326700B1 (fr)
NZ (1)	NZ528752A (fr)
OA (1)	OA12626A (fr)
PA (1)	PA8549301A1 (fr)
PE (1)	PE20030135A1 (fr)
PL (1)	PL367680A1 (fr)
PT (1)	PT1404653E (fr)
RS (1)	RS50712B (fr)
SI (1)	SI1404653T1 (fr)
SK (1)	SK287806B6 (fr)
TN (1)	TNSN03146A1 (fr)
TW (2)	TW200628447A (fr)
UA (1)	UA75660C2 (fr)
UY (1)	UY27360A1 (fr)
WO (1)	WO2003002533A1 (fr)
ZA (1)	ZA200307818B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60144284D1 (de)	2000-11-01	2011-05-05	Millennium Pharm Inc	Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
SK287806B6 (sk) *	2001-06-28	2011-10-04	Pfizer Products Inc.	Triamid-substituované indoly, benzofurány a benzotiofény ako inhibítory mikrozómového proteínu prenášajúceho triglyceridu (MTP) a/alebo sekrécie apolipoproteínu B (Apo B)
ATE536993T1 (de) *	2002-01-02	2011-12-15	Visen Medical Inc	Aminfunktionalisierte superparamagnetisierte nanoteilchen für die synthese von biokonjugaten
CN1964630A (zh) *	2003-02-13	2007-05-16	耶希瓦大学艾伯塔·爱恩斯坦医学院	通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
CN103585136A (zh) *	2003-05-20	2014-02-19	约翰霍普金斯大学	用于治疗肿瘤的邻苯二酚丁烷的释放的方法和组合物
CA2525517C (fr)	2003-06-19	2016-05-31	Applied Research Systems Ars Holding N.V.	Utilisation d'agents modulateurs de la conversion de prions
WO2005046644A1 (fr) *	2003-11-14	2005-05-26	Pfizer Products Inc.	Dispersions amorphes solides d'un inhibiteur de la mtp pour le traitement de l'obesite
GEP20084360B (en)	2004-02-04	2008-04-29	Pfizer Prod Inc	Substituted quinoline compounds
US7932268B2 (en)	2004-03-05	2011-04-26	The Trustees Of The University Of Pennsylvania	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
FR2873694B1 (fr) *	2004-07-27	2006-12-08	Merck Sante Soc Par Actions Si	Nouveaux aza-indoles inhibiteurs de la mtp et apob
WO2006041922A2 (fr) *	2004-10-08	2006-04-20	Dara Biosciences, Inc.	Agents, et procedes d'administration au systeme nerveux central
PA8660701A1 (es)	2005-02-04	2006-09-22	Pfizer Prod Inc	Agonistas de pyy y sus usos
US20070026079A1 (en) *	2005-02-14	2007-02-01	Louis Herlands	Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
JP2008542255A (ja) *	2005-05-27	2008-11-27	ファイザー・プロダクツ・インク	肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
DE102005027274A1 (de) *	2005-06-08	2006-12-14	Schering Ag	Inhibitoren der löslichen Adenylatzyklase
US7417066B2 (en)	2005-06-08	2008-08-26	Schering Ag	Inhibitors of soluble adenylate cyclase
WO2007015162A1 (fr) *	2005-08-04	2007-02-08	Pfizer Limited	Composes piperidinoyl-pyrrolidine et piperidinoyl-piperidine
EP1951220A2 (fr) *	2005-10-18	2008-08-06	Aegerion Pharmaceuticals	Compositions destinees a l'abbaissement du cholesterol serique et/ou des triglycerides
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
EP1954137A4 (fr) *	2005-11-18	2008-12-17	Janssen Pharmaceutica Nv	2-ceto-oxazoles en tant que modulateurs d'amide d'acide gras hydrolase
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
WO2007136413A2 (fr)	2005-12-22	2007-11-29	Visen Medical, Inc.	Nanoparticules d'oxyde métallique fluorescentes biocompatibles
US8383660B2 (en)	2006-03-10	2013-02-26	Pfizer Inc.	Dibenzyl amine compounds and derivatives
EP2674428B1 (fr)	2006-04-07	2016-04-06	Vertex Pharmaceuticals Incorporated	Modulateurs des transporteurs de cassettes de liaison de l'ATP
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
MX2009004314A (es)	2006-11-13	2009-05-05	Pfizer Prod Inc	Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos.
CN101663262B (zh)	2006-12-01	2014-03-26	百时美施贵宝公司	用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
CA2673290A1 (fr) *	2006-12-21	2008-07-03	Aegerion Pharmaceuticals, Inc.	Procedes de traitement de l'obesite a l'aide d'une combinaison comprenant un inhibiteur de mtp et un inhibiteur de l'absorption du cholesterol
US8221721B2 (en)	2007-02-09	2012-07-17	Visen Medical, Inc.	Polycyclo dyes and use thereof
WO2008100423A1 (fr) *	2007-02-09	2008-08-21	Sirtris Pharmaceuticals, Inc.	Inhibiteurs de protéines microsomiques de transport des triglycérides de l'intestin
EP2520561B1 (fr)	2007-06-08	2016-02-10	MannKind Corporation	Inhibiteurs IRE-1A
WO2009014674A1 (fr) *	2007-07-23	2009-01-29	Sirtris Pharmaceuticals, Inc.	Hétérocyclylamides comme inhibiteurs de la protéine de transport de triglycérides microsomal de l'intestin
JP5571000B2 (ja) *	2008-01-16	2014-08-13	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	メトフォルミンおよびｍｔｐ阻害剤の組み合わせ物
US20090197947A1 (en) *	2008-02-01	2009-08-06	The Research Foundation Of State University Of New York	Medicaments and methods for lowering plasma lipid levels and screening drugs
CN102781914B (zh) *	2010-01-06	2014-09-17	武田药品工业株式会社	吲哚衍生物
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX353408B (es)	2010-04-22	2018-01-11	Vertex Pharma	Proceso para producir compuestos de cicloalquilcarboxamido-indol.
US9409880B2 (en) *	2011-01-20	2016-08-09	The Regents Of The University Of Colorado, A Body Corporate	Modulators of TLR3/dsRNA complex and uses thereof
CN102108070B (zh) *	2011-01-26	2013-05-22	上海优贝德生物医药有限公司	5-氨基苯并呋喃-2-甲酸酯及其中间体的制备方法
AR092857A1 (es)	2012-07-16	2015-05-06	Vertex Pharma	Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
EP2963013A4 (fr)	2013-02-27	2016-09-14	Shionogi & Co	Dérivés d'indole et d'azaindole ayant chacun une activité d'activation d'ampk
US9624172B2 (en)	2014-02-17	2017-04-18	Hetero Research Foundation	Polymorphs of lomitapide and its salts
CN103880797B (zh) *	2014-03-26	2015-12-02	沈阳大学	苯并呋喃类化合物及其医药用途
RU2744460C2 (ru)	2014-04-15	2021-03-09	Вертекс Фармасьютикалз Инкорпорейтед	Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
MA41051B1 (fr)	2014-10-06	2020-11-30	Vertex Pharma	Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
CA3019380A1 (fr)	2016-03-31	2017-10-05	Vertex Pharmaceuticals Incorporated	Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
CN109803962B (zh)	2016-09-30	2022-04-29	弗特克斯药品有限公司	囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物
MD3551622T2 (ro)	2016-12-09	2021-03-31	Vertex Pharma	Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
US11253509B2 (en)	2017-06-08	2022-02-22	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
MA49631A (fr)	2017-07-17	2020-05-27	Vertex Pharma	Méthodes de traitement de la fibrose kystique
JP7121794B2 (ja)	2017-08-02	2022-08-18	バーテックスファーマシューティカルズインコーポレイテッド	ピロリジン化合物を調製するためのプロセス
WO2019079760A1 (fr)	2017-10-19	2019-04-25	Vertex Pharmaceuticals Incorporated	Formes cristallines et compositions de modulateurs de cftr
EP3720849A2 (fr)	2017-12-08	2020-10-14	Vertex Pharmaceuticals Incorporated	Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (fr)	2018-04-13	2021-02-17	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
US20230285376A1 (en)	2020-07-29	2023-09-14	Amryt Pharmaceuticals Inc.	Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
US12029718B2 (en)	2021-11-09	2024-07-09	Cct Sciences, Llc	Process for production of essentially pure delta-9-tetrahydrocannabinol
CN112608271A (zh) *	2020-11-26	2021-04-06	安润医药科技（苏州）有限公司	酰胺衍生物及其在制备ep4受体拮抗剂中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4022900A (en)	1970-09-09	1977-05-10	Marion Laboratories, Inc.	Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
US4397855A (en)	1981-06-26	1983-08-09	Warner-Lambert Company	4-(Substituted)-α, α-dimethyl-1-piperazine pentanoic acids and derivatives as anti-arteriosclerotic agents and method
US4647576A (en) *	1984-09-24	1987-03-03	Warner-Lambert Company	Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US5416009A (en)	1991-01-23	1995-05-16	The United States Of America	Nucleotide molecule encoding a specific Onchocerca volvulus antigen for the immunodiagnosis of onchocerciasis
CA2091102C (fr)	1992-03-06	2009-05-26	John R. Ii Wetterau	Proteine de transfert de triglycerides microsomaux
US5595872A (en)	1992-03-06	1997-01-21	Bristol-Myers Squibb Company	Nucleic acids encoding microsomal trigyceride transfer protein
GB9225141D0 (en)	1992-12-01	1993-01-20	Smithkline Beecham Corp	Chemical compounds
US5739135A (en)	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
FR2723739B1 (fr) *	1994-08-19	1997-02-14	Sanofi Sa	Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
WO1996040640A1 (fr) *	1995-06-07	1996-12-19	Pfizer Inc.	DERIVES DE BIPHENYL-2-ACIDE CARBOXYLIQUE-TETRAHYDRO-ISOQUINOLEINE-6-YL AMIDES, PREPARATION DE CES AMIDES ET UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE TRIGLYCERIDE MICROSOMAL ET/OU DE LA SECRETION D'APOLIPOPROTEINES B (Apo B)
EP1181954A3 (fr)	1995-06-07	2002-08-21	Pfizer Inc.	Derives de biphenyl-2-acide carboxylique-tetrahydro-isoquinoleine-6-yl amides, preparation de ces amides et utilisation en tant qu'inhibiteurs de la proteine de transfert de triglyceride microsomal et/ou de la secretion d'apolipoproteines b (apo b)
ATE233734T1 (de)	1995-06-07	2003-03-15	Pfizer	Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6 yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
CA2244729C (fr)	1996-02-02	2005-08-23	Merritt, Brigitte	Dispositif permettant de travailler un brin de materiau plastique
US5827875A (en)	1996-05-10	1998-10-27	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
NZ335162A (en)	1996-11-27	2000-01-28	Pfizer	Apo b-secretion/mtp inhibitory amides
WO1998027979A1 (fr)	1996-12-20	1998-07-02	Bristol-Myers Squibb Company	Inhibiteurs heterocycliques de la proteine de transfert des triglycerides microsomiques et methode associee
US6066653A (en)	1997-01-17	2000-05-23	Bristol-Myers Squibb Co.	Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US5968950A (en)	1997-06-23	1999-10-19	Pfizer Inc	Apo B-secretion/MTP inhibitor hydrochloride salt
TW460478B (en) *	1997-08-15	2001-10-21	Chugai Pharmaceutical Co Ltd	Phenethylamine derivatives
JP2959765B2 (ja)	1997-12-12	1999-10-06	日本たばこ産業株式会社	３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
HU227568B1 (en)	1997-12-24	2011-08-29	Sanofi Aventis Deutschland	Indole derivatives, as inhibitors os factor xa
CA2332511A1 (fr)	1998-05-22	1999-12-02	Nippon Shinyaku Co., Ltd.	Compositions destinees a diminuer l'activite mtp
WO1999063929A2 (fr)	1998-06-08	1999-12-16	Advanced Medicine, Inc.	Inhibiteurs multiliaison de proteine triglyceride transferase microsomique
CO5090829A1 (es) *	1998-07-21	2001-10-30	Novartis Ag	Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
US6197798B1 (en)	1998-07-21	2001-03-06	Novartis Ag	Amino-benzocycloalkane derivatives
DE60022508T2 (de) *	1999-06-14	2006-06-08	Eli Lilly And Co., Indianapolis	Inhibitoren von serin proteasen
DE19933926A1 (de)	1999-07-20	2001-01-25	Boehringer Ingelheim Pharma	Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19945594A1 (de) *	1999-09-23	2001-03-29	Boehringer Ingelheim Pharma	Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2325358C (fr) *	1999-11-10	2005-08-02	Pfizer Products Inc.	Amides de l'acide 7-¬(4'-trifluoromethylbiphenyl-2-carbonyl)amino\|-quinoleine-3-carboxylique et methodes pour inhiber la secretion d'apolipoproteine b
DE19963234A1 (de)	1999-12-27	2002-01-24	Boehringer Ingelheim Pharma	Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19963235A1 (de)	1999-12-27	2001-07-05	Boehringer Ingelheim Pharma	Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2001053260A1 (fr)	2000-01-18	2001-07-26	Novartis Ag	Carboxamides utilises comme inhibiteurs de proteine de transfert triglyceridique microsomique et de la secretion d'apolipoproteine b
AU2001262185A1 (en)	2000-04-10	2001-10-23	Novartis Ag	Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0013346D0 (en)	2000-06-01	2000-07-26	Glaxo Group Ltd	Therapeutic benzamide derivatives
GB0013383D0 (en)	2000-06-01	2000-07-26	Glaxo Group Ltd	Therapeutic benzamide derivatives
GB0013378D0 (en)	2000-06-01	2000-07-26	Glaxo Group Ltd	Use of therapeutic benzamide derivatives
US20020032238A1 (en)	2000-07-08	2002-03-14	Henning Priepke	Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
DE10033337A1 (de)	2000-07-08	2002-01-17	Boehringer Ingelheim Pharma	Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2816940A1 (fr)	2000-11-23	2002-05-24	Lipha	Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
GB0109287D0 (en)	2001-04-12	2001-05-30	Glaxo Group Ltd	Therapeutic benzamide derivatives
SK287806B6 (sk) *	2001-06-28	2011-10-04	Pfizer Products Inc.	Triamid-substituované indoly, benzofurány a benzotiofény ako inhibítory mikrozómového proteínu prenášajúceho triglyceridu (MTP) a/alebo sekrécie apolipoproteínu B (Apo B)
BR0306292A (pt)	2002-02-28	2004-08-24	Japan Tobacco Inc	Composto de éster e uso medicinal do mesmo

2002
- 2002-05-24 SK SK1610-2003A patent/SK287806B6/sk not_active IP Right Cessation
- 2002-05-24 HU HU0400348A patent/HU229551B1/hu not_active IP Right Cessation
- 2002-05-24 EE EEP200400040A patent/EE05452B1/xx not_active IP Right Cessation
- 2002-05-24 CN CN2006100941142A patent/CN1880304B/zh not_active Expired - Fee Related
- 2002-05-24 NZ NZ528752A patent/NZ528752A/en not_active IP Right Cessation
- 2002-05-24 KR KR1020037017167A patent/KR100575919B1/ko not_active Expired - Fee Related
- 2002-05-24 AU AU2002307839A patent/AU2002307839B2/en not_active Ceased
- 2002-05-24 BR BR0210616-7A patent/BR0210616A/pt active Search and Examination
- 2002-05-24 EA EA200301310A patent/EA007008B1/ru not_active IP Right Cessation
- 2002-05-24 RS YUP-1004/03A patent/RS50712B/sr unknown
- 2002-05-24 ES ES02780923T patent/ES2307799T3/es not_active Expired - Lifetime
- 2002-05-24 AT AT02780923T patent/ATE405548T1/de active
- 2002-05-24 SI SI200230732T patent/SI1404653T1/sl unknown
- 2002-05-24 GE GE5350A patent/GEP20053720B/en unknown
- 2002-05-24 HR HR20031051A patent/HRP20031051B1/xx not_active IP Right Cessation
- 2002-05-24 CZ CZ20033558A patent/CZ20033558A3/cs unknown
- 2002-05-24 UA UA20031212657A patent/UA75660C2/uk unknown
- 2002-05-24 MX MXPA03011707A patent/MXPA03011707A/es active IP Right Grant
- 2002-05-24 EP EP02780923A patent/EP1404653B1/fr not_active Expired - Lifetime
- 2002-05-24 PT PT02780923T patent/PT1404653E/pt unknown
- 2002-05-24 DE DE60228447T patent/DE60228447D1/de not_active Expired - Lifetime
- 2002-05-24 IL IL15851602A patent/IL158516A0/xx not_active IP Right Cessation
- 2002-05-24 OA OA1200300327A patent/OA12626A/en unknown
- 2002-05-24 CA CA002451474A patent/CA2451474C/fr not_active Expired - Fee Related
- 2002-05-24 TN TNPCT/IB2002/001876A patent/TNSN03146A1/fr unknown
- 2002-05-24 WO PCT/IB2002/001876 patent/WO2003002533A1/fr not_active Ceased
- 2002-05-24 KR KR1020057025027A patent/KR100575944B1/ko not_active Expired - Fee Related
- 2002-05-24 DK DK02780923T patent/DK1404653T3/da active
- 2002-05-24 GE GEAP20027236A patent/GEP20063720B/en unknown
- 2002-05-24 JP JP2003508914A patent/JP4139325B2/ja not_active Expired - Lifetime
- 2002-05-24 PL PL02367680A patent/PL367680A1/xx unknown
- 2002-05-24 CN CN028130219A patent/CN1522246B/zh not_active Expired - Fee Related
- 2002-06-20 US US10/177,858 patent/US6720351B2/en not_active Expired - Fee Related
- 2002-06-21 TW TW094146513A patent/TW200628447A/zh unknown
- 2002-06-21 TW TW091113664A patent/TWI313264B/zh not_active IP Right Cessation
- 2002-06-26 AR ARP020102408A patent/AR036158A1/es active IP Right Grant
- 2002-06-26 MY MYPI20022415A patent/MY129328A/en unknown
- 2002-06-27 GT GT200200136A patent/GT200200136A/es unknown
- 2002-06-27 AP APAP/P/2002/002567A patent/AP1649A/en active
- 2002-06-27 PE PE2002000580A patent/PE20030135A1/es not_active Application Discontinuation
- 2002-06-27 UY UY27360A patent/UY27360A1/es unknown
- 2002-06-28 PA PA20028549301A patent/PA8549301A1/es unknown
2003
- 2003-08-13 US US10/639,855 patent/US6949572B2/en not_active Expired - Fee Related
- 2003-08-13 US US10/639,854 patent/US6979692B2/en not_active Expired - Fee Related
- 2003-10-07 ZA ZA200307818A patent/ZA200307818B/en unknown
- 2003-10-09 IS IS6988A patent/IS2603B/is unknown
- 2003-11-17 CR CR7151A patent/CR7151A/es not_active Application Discontinuation
- 2003-12-16 NO NO20035607A patent/NO326700B1/no not_active IP Right Cessation
- 2003-12-22 MA MA27457A patent/MA27045A1/fr unknown
- 2003-12-22 BG BG108487A patent/BG108487A/bg unknown
- 2003-12-23 EC EC2003004925A patent/ECSP034925A/es unknown
2005
- 2005-08-02 US US11/196,563 patent/US7482368B2/en not_active Expired - Fee Related
2006
- 2006-02-10 US US11/351,571 patent/US7348355B2/en not_active Expired - Fee Related
2008
- 2008-10-13 CY CY20081101126T patent/CY1108407T1/el unknown

Also Published As

Publication number	Publication date
EA200301310A1 (ru)	2004-06-24
JP4139325B2 (ja)	2008-08-27
CN1880304A (zh)	2006-12-20
DE60228447D1 (de)	2008-10-02
HK1096665A1 (en)	2007-06-08
US20050288335A1 (en)	2005-12-29
IS6988A (is)	2003-10-09
US20040087625A1 (en)	2004-05-06
NO20035607D0 (no)	2003-12-16
UA75660C2 (en)	2006-05-15
CY1108407T1 (el)	2014-02-12
CA2451474A1 (fr)	2003-01-09
KR20040013006A (ko)	2004-02-11
BG108487A (bg)	2005-04-30
HUP0400348A3 (en)	2011-07-28
PT1404653E (pt)	2008-09-23
NO326700B1 (no)	2009-02-02
TW200628447A (en)	2006-08-16
MXPA03011707A (es)	2004-03-19
CN1522246B (zh)	2010-04-21
GEP20063720B (en)	2006-01-10
HU229551B1 (hu)	2014-01-28
GEP20053720B (en)	2006-01-10
KR20060006107A (ko)	2006-01-18
WO2003002533A1 (fr)	2003-01-09
PA8549301A1 (es)	2003-02-14
PL367680A1 (en)	2005-03-07
IL158516A0 (en)	2004-05-12
NZ528752A (en)	2006-06-30
KR100575944B1 (ko)	2006-05-02
TWI313264B (en)	2009-08-11
HK1064369A1 (zh)	2005-01-28
CN1522246A (zh)	2004-08-18
CR7151A (es)	2004-02-23
US20030187053A1 (en)	2003-10-02
EE200400040A (et)	2004-06-15
CN1880304B (zh)	2010-11-24
SK16102003A3 (sk)	2004-08-03
BR0210616A (pt)	2004-09-28
US6720351B2 (en)	2004-04-13
AU2002307839B2 (en)	2006-03-16
CA2451474C (fr)	2009-06-16
RS50712B (sr)	2010-06-30
GT200200136A (es)	2003-05-15
DK1404653T3 (da)	2008-10-06
AR036158A1 (es)	2004-08-18
ATE405548T1 (de)	2008-09-15
ZA200307818B (en)	2004-10-07
EP1404653B1 (fr)	2008-08-20
US6949572B2 (en)	2005-09-27
TNSN03146A1 (fr)	2005-12-23
EP1404653A1 (fr)	2004-04-07
US7482368B2 (en)	2009-01-27
UY27360A1 (es)	2003-01-31
US7348355B2 (en)	2008-03-25
MY129328A (en)	2007-03-30
PE20030135A1 (es)	2003-03-03
AP1649A (en)	2006-08-07
KR100575919B1 (ko)	2006-05-02
HRP20031051A2 (en)	2005-08-31
US20060194772A1 (en)	2006-08-31
US20050080108A1 (en)	2005-04-14
OA12626A (en)	2006-06-13
SI1404653T1 (sl)	2008-12-31
SK287806B6 (sk)	2011-10-04
ES2307799T3 (es)	2008-12-01
HRP20031051B1 (en)	2012-01-31
US6979692B2 (en)	2005-12-27
HUP0400348A2 (hu)	2004-12-28
ECSP034925A (es)	2004-02-26
RS100403A (sr)	2007-02-05
EA007008B1 (ru)	2006-06-30
IS2603B (is)	2010-04-15
CZ20033558A3 (cs)	2004-04-14
EE05452B1 (et)	2011-08-15
JP2004537541A (ja)	2004-12-16
AP2002002567A0 (en)	2002-06-30

Publication	Publication Date	Title
MA27045A1 (fr)	2004-12-20	Indoles, benzofurannes et benzothiophenes a substituant triamide, utiles comme inhibiteurs de secretion de la proteine de transfert des triglycerides microsomaux et/ou de l'apolipoproteine b (apo b)
MA27034A1 (fr)	2004-12-20	Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle
EP1489174A4 (fr)	2005-03-16	Procede de modification des proprietes d'une proteine
NO20004219D0 (no)	2000-08-23	Inhibitorer av fosfolipaseenzymer
NO20004220L (no)	2000-10-05	Inhibitorer av fosfolipaseenzymer
MA26935A1 (fr)	2004-12-20	Compositions pharmaceutiques d'inhibiteurs de la proteine de transfert d'ester de cholesteryle
NO995852L (no)	2000-01-31	Ny form av S-omeprazol
NO20004533D0 (no)	2000-09-11	Diskrimineringsinnretning av automatisk modulasjonstype og diskriminerings-fremgangsmÕte for diskriminering av mange slag av modulasjonstyper
NO993717D0 (no)	1999-07-30	Anvendelse av gastrointestinale lipase-inhibitorer
ATE267184T1 (de)	2004-06-15	Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung zur hemmung der hormonsensitiven lipase
DE60009888D1 (de)	2004-05-19	Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
NO20031359D0 (no)	2003-03-25	Sammensetninger og fremgangsmåter for rensing av kontaktlinser
DE60143197D1 (de)	2010-11-18	Kristalline form von 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- ä2,3'ü bipyridinyl und herstellungsverfahren hierfür
DE60001735D1 (de)	2003-04-24	1-aminotriazolo 4,3-a chinazolin-5-one und/oder -thione inhibitoren von phosphodiesterasen iv
EP1405912A4 (fr)	2005-01-05	Ecarine genetiquement modifiee et procede d'elaboration
AU2001262185A1 (en)	2001-10-23	Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
ATE253059T1 (de)	2003-11-15	Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung als lipase-hemmer
NO20040059L (no)	2004-01-07	Benzo[G]kinolinderivater for behandling av glaukom og myopi
PT1402109T (pt)	2017-12-18	Resumo
EP1451138A4 (fr)	2005-06-15	Methode permettant d'inverser le processus de maladies cardio-vasculaires et de prevenir ces dernieres
FR2787121B1 (fr)	2003-09-12	Nouvelle methode d'isolement et de selection de genes codant pour des enzymes, et milieu de culture approprie
FI104122B1 (fi)	1999-11-15	Laakerin kevennys
DE60037782D1 (de)	2008-03-06	Schicht-2 "Link-handler" sowie entsprechendes Verbindungsverfahren
AU8626398A (en)	1999-01-25	Inhibitors of the phosphodiesterase-4 for the treatment of allergic rhinitis
AU2002223583A1 (en)	2002-04-15	Method of characterising optical amplifiers